Drug
Ponesimod clinical trials
Also written ACT-128800.
- studies test it
- 16
- open now
- 2
- in phase 3
- 5
- first study started
- 2008
Keep track of what changes. Save the ponesimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
16 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2022 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 0
Actelion (13) · Vanda Pharmaceuticals (2) · Janssen Pharmaceutica N.V., Belgium (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ponesimod is read from its arms, and is right about nine times in ten.
Testing it · 16
- Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisRecruitingPhase 3Vanda PharmaceuticalsNCT07362017Written as Ponesimod
- Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisRecruitingPhase 3Vanda PharmaceuticalsNCT07686081Written as Ponesimod
- Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisCompletedPhase 3ActelionNCT03232073Written as Ponesimod
- A Study of Ponesimod in Healthy Adult ParticipantsCompletedPhase 1Janssen Pharmaceutica N.V., BelgiumNCT05552196Written as Ponesimod
- Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple SclerosisCompletedPhase 2ActelionNCT01006265Written as ACT-128800 Dose 1
- Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisCompletedPhase 2ActelionNCT01093326Written as Ponesimod 10 mg
- Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisCompletedPhase 3ActelionNCT02425644Written as ponesimod
- ACT-128800 in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 2ActelionNCT01208090Written as ACT-128800
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHDTerminatedPhase 2ActelionNCT02461134Written as Ponesimod
- Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)TerminatedPhase 3ActelionNCT02907177Written as Ponesimod
- Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male SubjectsCompletedPhase 1ActelionNCT02068235Written as Ponesimod 5mg i.v.
- Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female SubjectsCompletedPhase 1ActelionNCT02223832Written as ACT-128800
- Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female SubjectsCompletedPhase 1ActelionNCT02136888Written as Ponesimod 10 mg
- Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male SubjectsCompletedPhase 1ActelionNCT02126956Written as ACT-128800
- Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy SubjectsCompletedPhase 1ActelionNCT02029482Written as ACT-128800
- ACT-128800 in PsoriasisCompletedPhase 2ActelionNCT00852670Written as ACT-128800
Codes
What other systems call ponesimod · ClinicalTrials.gg INT005646
- MeSH (NLM) C550169ponesimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5G7AKV2MKPPONESIMODConfirmed FDA, NLM
- RxNorm 2532300One source FDA
- NCI Thesaurus C96534PonesimodOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C550169 | ponesimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5G7AKV2MKP | PONESIMOD | Confirmed FDA, NLM |
| RxNorm | 2532300 | — | One source FDA |
| NCI Thesaurus | C96534 | Ponesimod | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.